"According to a Sept. 16 press release, three separate doses of the new drug (6 mg, 12 mg, and 36 mg) demonstrated "significant improvements" in body weight reduction compared to a placebo at 72 weeks. "Obesity is a complex, global health challenge - and patients need treatment options that are both effective and easy to integrate into everyday life," Sean Wharton, M.D., director at Wharton Medical Clinic and lead investigator, said in the release."
"Wharton continued, "In this Phase 3 study, orforglipron demonstrated strong efficacy results and safety consistent with the GLP-1 class, reinforcing its potential as a first-line treatment in primary care. Additionally, orforglipron could help reduce known markers of cardiovascular risk associated with obesity and support meaningful improvements in public health." Notably, the highest dose of the new drug lowered A1C more than Novo Nordisk's drug, semaglutide, bringing it down by 1.9 percentage points compared to 1.5 percentage points."
In a Phase 3 trial, oral GLP-1 pill orforglipron (6 mg, 12 mg, 36 mg) produced significant body-weight reductions versus placebo at 72 weeks. The highest dose reduced A1C by 1.9 percentage points compared with 1.5 points for semaglutide and produced an average 8.2% weight loss versus 5.3% with semaglutide. Safety findings were consistent with the GLP-1 class. Investigators noted potential for first-line use in primary care and possible reductions in cardiovascular risk markers. Eli Lilly plans regulatory submissions for type 2 diabetes next year, with experts pointing to an FDA pilot program that could accelerate review from ten months to two months.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]